Bayer has halted the acceptance of new patients into its early access scheme, amidst an ongoing dispute with HMRC regarding tax liabilities on free-of-charge medicines. This decision has raised concerns
Bayer has halted the acceptance of new patients into its early access scheme, amidst an ongoing dispute with HMRC regarding tax liabilities on free-of-charge medicines. This decision has raised concerns






